Coronavirus Disease-2019 (COVID-19) is caused by SARS-CoV-2, a betacoronavirus highly similar to SARS (now SARS-CoV-1) ([@R1], [@R2]). An urgent need exists for treatment strategies, and repurposed FDA-approved drugs with existing supply chains and well-characterized pharmacologic properties represent a rapid and efficient approach toward COVID-19 therapeutics ([@R3]).

Enzymes encoded by SARS-CoV-2 are attractive drug targets, including PLpro, an essential cysteine protease activity within the nsp3 protein ([@R4]). PLpro cleaves the pp1a polyprotein at three sites, generating mature nsp1, 2 and 3 proteins. The PLpro recognition site (LXGG) is also found at the C-terminus of ubiquitin and ISG15, an antiviral ubiquitin-like modifier, although SARS-CoV-1 and -2 PLpro preferentially catalyze de-ISGylation over de-ubiquitylation ([@R5], [@R6]). Therapeutic inhibition of PLpro would therefore be predicted to have two antiviral effects: restoration of the antiviral effect of ISGylation and inhibition of viral replication by blocking polyprotein cleavage. Further, de-ISGylation by PLpro, through generation of free (unconjugated) ISG15, enhances the secretion and extracellular signaling function of ISG15, which in turn promotes pro-inflammatory cytokine production from cells of the immune system ([@R7]). Therefore, a potential third effect of inhibiting PLpro would be a decrease in pro-inflammatory "cytokine storms" associated with COVID-19 ([@R8]).

6-Thioguanine (6-TG) is an FDA-approved drug that has been used in the clinic since the 1950s, originally for the treatment of childhood leukemias and subsequently for treatment of inflammatory bowel and Crohn's disease ([@R9]). 6-TG was previously reported to inhibit the SARS-CoV-1 and MERS PLpro catalytic domain *in vitro* ([@R10], [@R11]), with an IC50 of 5 µM and 24.4 µM, respectively, however there was no further follow up of its ability to inhibit de-ISGylation or viral polyprotein cleavage in cells or its ability to inhibit viral replication. [Fig. 1A](#F1){ref-type="fig"} shows that co-expression of PLpro (residues 746-1061 of nsp3) with ISG15 and its conjugation enzymes (Uba7, Ube2L6, and Herc5) in HEK293T cells resulted in nearly complete loss of ISG15 conjugates, while expression of the active-site C-to-A variant of PLpro (C856 of nsp3; PLpro^CA^) was inactive. Addition of 6-TG resulted in a dose-dependent inhibition of PLpro de-ISGylation activity, with half-maximal inhibition at approximately 0.1 µM ([Fig. 1A](#F1){ref-type="fig"}; quantitation shown in [Supplementary Fig. 1A](#SD1){ref-type="supplementary-material"}).

The PLpro domain, located within nsp3, generates mature nsp-1, 2 and 3 proteins from the pp1a polyprotein through self-catalyzed cleavage reactions ([Fig. 1B](#F1){ref-type="fig"}, schematic). We determined whether 6-TG inhibited polyprotein processing, as this is an essential function of Plpro and the natural context in which PLpro is expressed. An N-terminally TAP-tagged fusion of nsp1, 2 and 3 (TAP-nsp123^WT^) was expressed in HEK293T cells ([Fig. 1B](#F1){ref-type="fig"}, schematic), as well as the active-site C-to-A variant (TAP-nsp123^CA^). The fusion protein was detected with anti-TAP antibody, and TAP-nsp1 was expressed separately as a size marker for the fully processed fusion protein. As shown in [Fig. 1B](#F1){ref-type="fig"}, expression of TAP-nsp123^WT^ resulted primarily in a product the size of TAP-nsp1 (42 kD), as expected if the fusion protein was fully processed, while expression of TAP-nsp123^CA^ resulted in the expected full-length protein (\~336 kD) along with several breakdown products of the full-length protein. Increasing concentrations of 6-TG inhibited PLpro-mediated processing of the TAP-nsp123^WT^ polyprotein, with loss of the TAP-nsp1 product and accumulation of the full-length fusion protein, with the same pattern of breakdown products seen with the TAP-nsp123^CA^ protein. Half-maximal inhibition of polyprotein cleavage occurred between 0.1 and 0.5 µM (quantitation shown in [Supplementary Fig. 1B](#SD1){ref-type="supplementary-material"}). This result indicates that 6-TG inhibits an essential function of PLpro activity and that it inhibits PLpro when it is expressed in the context of the full-length nsp3 protein.

In addition to its function as a ubiquitin-like modifier, free (unconjugated) ISG15 exits cells and signals to LFA-1-expressing cells of the immune system (*e.g*., NK cells, T cells) to release specific cytokines, including IFN-γ and IL-10 ([@R7], [@R12]), while ISG15 conjugates are retained in cells. Therefore, a secondary effect of PLpro-mediated de-ISGylation is the enhanced secretion of ISG15 ([@R7]). We determined whether 6-TG would block this effect. [Fig. 2A](#F2){ref-type="fig"} shows that expression of PLpro in HEK293T cells led to decreased intracellular ISG15 conjugates (upper blot, total cell lysates) and increased free ISG15 in the extracellular space (lower blot, IP-western of ISG15 from cell culture supernatants), and that 6-TG not only restored intracellular conjugates but also blocked the production of free extracellular ISG15.

IFN-γ, IL-10 and IL-6 are associated with uncontrolled cytokine release syndrome and have been shown to be elevated in COVID-19 patients ([@R13], [@R14]). The complete range of cytokines affected by extracellular ISG15 signaling is unknown, but the relationship of ISG15 to IFN-γ and IL-10 ([@R12]) led us to test whether ISG15 also induced the secretion of IL-6 from human PBMCs. In a trans-well culture system, HEK293T cells (lower chamber) were transfected with ISG15, with or without the ISG15 conjugation enzymes (E1/E2/E3) and/or PLpro. PBMCs were placed in the upper chamber, separated from the lower chamber by a 0.4 micron membrane. In this system, ISG15 released from cells in the lower chamber signals to LFA-1-expressing cells in the upper chamber, and cytokine release in the upper chamber is measured by ELISA ([@R7]). [Fig. 2B](#F2){ref-type="fig"} shows that expression of ISG15, alone, in the HEK293T cells led to secretion of IL-6 from PBMCs, and this effect was diminished when the conjugation enzymes were co-expressed with ISG15 (compare lanes 1, 3, and 5). De-ISGylation catalyzed by PLpro resulted in enhanced IL-6 secretion (compare lanes 5 and 7), and the addition of 6-TG reversed the effect of PLpro, leading to diminished IL-6 production (compare lanes 7 and 8). These results identify IL-6 as an additional cytokine that is responsive to extracellular ISG15 signaling and suggest that PLpro may be at least partially responsible for enhanced cytokine responses in COVID-19 patients. Therapeutically, 6-TG inhibition of PLpro might therefore have the additional benefit of limiting excessive cytokine responses associated with poor patient outcomes.

6-TG was next analyzed for its ability to inhibit SARS-CoV-2 replication (strain 2019 n-CoV/USA_WA1/2020; *18*) in Vero-E6 African green monkey kidney cells and in the Calu3 human lung epithelial cell line. As shown in [Fig. 3](#F3){ref-type="fig"}, 6-TG inhibited viral replication in Vero-E6 cells with a half-maximal effective concentration (EC50) of 0.647 ± 0.374 μM. By comparison, Remdesivir inhibited SARS-CoV-2 replication in Vero-E6 cells similarly, with an EC50 of 0.77 µM ([@R15]). 6-TG inhibited virus replication in Calu3 cells at a lower EC50, 0.061 ± 0.049 μM. While the basis of the difference between the two cell lines is not known, cell lines can vary significantly with respect to thiopurine uptake and metabolism ([@R16]). 6-TG did not elicit significant cellular toxicity in either Vero-E6 or Calu3 cells (CC50 \>50 μM), yielding selectivity indices (SI) of \>77 in Vero-E6 cells and \>819 Calu3 cells. Together, the results presented here indicate that 6-Thioguanine is a direct-acting SARS-CoV-2 antiviral, inhibiting PLpro de-ISGylation, polyprotein cleavage, and viral replication at submicromolar concentrations.

To our knowledge, 6-TG is the first identified FDA-approved inhibitor of PLpro demonstrated to inhibit SARS-CoV-2 replication. 6-TG is a widely available orally delivered generic drug on the World Health Organization list of essential medicines ([@R17]). Dosing regimens vary significantly depending on its use, from 10 mg per day for long-term treatment of inflammatory diseases, to up to 3 mg/kg/day in acute lymphocytic leukemia treatments ([@R18]). While toxicity can be significant at higher dosages, it is anticipated that its use as an antiviral would be over a relatively short time period and that toxicity issues would likely be minimal. We propose that the results presented here warrant the initiation of human clinical trials of 6-TG as a SARS-CoV-2 therapeutic. As PLpro is a conserved and essential enzymatic activity of the beta coronaviruses, 6-TG may prove useful in the current and future coronavirus pandemics and as a complement to other antivirals in development.
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![6-TG inhibits PLpro mediated de-ISGylation and viral polyprotein cleavage.\
**A.** The structure of 6-Thioguanine is shown. HEK293T cells were transfected with plasmids expressing FLAG-ISG15 and the ISG15 E1/E2/E3 enzymes and 0.2 μg of PLpro plasmid (WT or CA) where indicated. 6-TG was added at the time of transfection at the indicated final concentrations (μM). Total cell lysates were prepared 48 hours post-transfection and analyzed by immunoblotting to detect FLAG-ISG15 and FLAG-ISG15 conjugates. **B.** (Top) Schematic representation of the TAP-nsp123 fusion protein, with molecular masses of subdomains indicated. Arrows indicate sites of PLpro-catalyzed cleavage. (Bottom) HEK293T cells were transfected with plasmids expressing either TAP-nsp1, TAP-nsp123^WT^ or TAP-nsp123^CA^. 6-TG was added at the time of transfection at the indicated final concentrations (μM) and total cell lysates were prepared 48 hours post-transfection and analyzed by immunoblotting with anti-TAP antibody. Bands corresponding to TAP-nsp1 and the full-length fusion proteins are indicated. Bracketed bands (\*) represent breakdown products of the full-length WT or CA fusion proteins.](nihpp-2020.07.01.183020-f0001){#F1}

![6-TG inhibits PLpro-enhanced extracellular ISG15 signaling and production of IL-6 from PBMCs.\
**A.** HEK293T cells were transfected and treated with 6-TG, as indicated. Total cell lysates were prepared and cell culture supernatants were collected 48 hours post-transfection. The upper panel shows a FLAG-ISG15 immunoblot analysis of cell lysates and the lower panel shows a FLAG-ISG15 immunoblot of an anti-FLAG immunoprecipitation of the cell culture supernatants. **B.** HEK293T cells were plated in the lower chamber of a transwell plate and transfected with plasmids expressing FLAG-ISG15, the ISG15 E1/E2/E3 enzymes, and PLpro, as indicated. 6-TG (0.5 µM) was added to the cells at the time of transfection. PMBCs were added to the upper chamber of the transwell plate; supernatants were collected from the upper chamber 24 hours post-transfection and assayed for IL-6 by ELISA. Significance was assessed by ordinary one-way ANOVA comparison to treatment with 6-TG alone. Asterisks indicate p-values: \*\*\*\*\<0.0001, and non-significant changes are indicated by ns.](nihpp-2020.07.01.183020-f0002){#F2}

![6-TG inhibits SARS-CoV-2 viral replication.\
Vero-E6 (**A, C**) and Calu3 (**B, D**) cells were treated with various concentrations of 6-TG and assessed for viability or were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.001. **A and B:** Cellular cytotoxicity of 6-TG was determined using a real-time SYTOX assay 48 hours post-treatment (closed squares) and the median cytotoxic concentration (CC50) was \>50 mM in both cell lines. Inhibition of viral replication was assayed by SARS-CoV-2 N1 RT-qPCR of cell supernatants 48 hours post-infection (closed circles) and the effective median concentration for inhibition (EC50) was determined. The left and right y-axis of each graph represent mean percent inhibition of virus yield/titer and mean percent cell viability at the indicated concentration of 6-TG. **C. and D.** Viral genome equivalents in the cell supernatants were quantified by SARS-CoV-2 N1 RT-qPCR. Data are means ± SED; n = 3 -- 5 biological replicates.](nihpp-2020.07.01.183020-f0003){#F3}
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